Company Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health.
The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult.
In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates.
The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Dr. Shankar Musunuri M.B.A., Ph.D. |
Contact Details
Address: 11 Great Valley Parkway Malvern, Pennsylvania 19355 United States | |
| Phone | 484-328-4701 |
| Website | ocugen.com |
Stock Details
| Ticker Symbol | OCGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001372299 |
| CUSIP Number | 67577C105 |
| ISIN Number | US67577C1053 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shankar Musunuri M.B.A., Ph.D. | Co-Founder, Chief Executive Officer and Chairman |
| Dr. Uday B. Kompella Ph.D. | Co-founder and Independent Director |
| Michael Breininger CPA, M.B.A. | Interim Chief Accounting Officer and Principal Financial Officer and Corporate Controller |
| Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research and Development |
| John Kouch J.D. | General Counsel |
| Tiffany J. Hamilton M.B.A. | Head of Corporate Communications |
| Dr. Durgaprasad Annavajjula Ph.D. | Vice President, Head of Program Management and Chief of Staff |
| Michael Shine M.B.A. | Senior Vice President of Commercial |
| Jyothy Pillai M.S. | Head of Regulatory and Quality |
| Dr. Huma Qamar CMI, M.D., M.P.H. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 8, 2024 | 8-K | Current Report |
| Jun 28, 2024 | 8-K | Current Report |
| Jun 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 6, 2024 | 8-K | Current Report |
| May 28, 2024 | ARS | Filing |
| May 28, 2024 | DEF 14A | Other definitive proxy statements |
| May 17, 2024 | PRE 14A | Other preliminary proxy statements |
| May 14, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | 8-A12G | Filing |